Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | DNM1 | Q05193 | 8/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19262110 | 1.00 | TSHR (0.52) | TSHRCYP3A4DNM1MEN1KMT2A | |
| SCHEMBL5932203 | 1.00 | TSHR (0.52) | TSHRCYP3A4DNM1MEN1KMT2A | |
| SCHEMBL24336335 | 0.97 | TSHR (0.50) | TSHRCYP3A4DNM1MEN1KMT2A | |
| SCHEMBL17188317 | 0.97 | TSHR (0.50) | TSHRCYP3A4DNM1MEN1KMT2A | |
| SCHEMBL237526 | 0.97 | — | — | |
| Ethylenediamine SCHEMBL27579634 | 0.97 | TSHR (0.55) | TSHRCYP3A4DNM1MEN1KMT2A | |
| SCHEMBL5933461 | 0.94 | TSHR (0.52) | TSHRCYP3A4DNM1MEN1KMT2A | |
| SCHEMBL5932795 | 0.94 | TSHR (0.52) | TSHRCYP3A4DNM1MEN1KMT2A | |
| SCHEMBL23406866 | 0.94 | TSHR (0.52) | TSHRCYP3A4DNM1MEN1KMT2A | |
| SCHEMBL12857146 | 0.94 | TSHR (0.52) | TSHRCYP3A4DNM1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067952-A1 | REPROGRAMMING UROKINASE INTO AN ANTIBODY-RECRUITING ANTICANCER AGENT | UNIV YALE (US) | 2024-02-29 | — | — | US | disclosed |
| US-20230381113-A1 | POLYMERS AND NANOPARTICLE FORMULATIONS FOR SYSTEMIC NUCLEIC ACID DELIVERY | THE JOHNS HOPKINS UNIVERSTY | 2023-11-30 | — | — | US | disclosed |
| US-20230295105-A1 | PIPERIDINEDIONE DERIVATIVES | INNOCURE THERAPEUTICS, INC. (KR) | 2023-09-21 | — | — | US | disclosed |
| US-20230250053-A1 | PROCESS FOR SYNTHESIZING TARGETING MOLECULES | BRISTOL-MYERS SQUIBB COMPANY | 2023-08-10 | — | — | US | disclosed |
| EP-4116298-A1 | PIPERIDINEDIONE DERIVATIVE | Innocure Therapeutics, Inc. (KR) | 2023-01-11 | — | — | EP | disclosed |
| US-11358988-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-14 | — | — | US | disclosed |
| US-11083682-B2 | Composition and method for improving and protecting keratins | COHERE BEAUTY, OMAHA, INC. | 2021-08-10 | — | — | US | disclosed |
| WO-2020198145-A1 | GENE DELIVERY PARTICLES TO INDUCE TUMOR-DERIVED ANTIGEN PRESENTING CELLS | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-10-01 | — | — | WO | disclosed |
| US-20200216498-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-09 | — | — | US | disclosed |
| US-20190275110-A1 | COMPOSITIONS IN THE FORM OF AN INJECTALE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2019-09-12 | — | — | US | disclosed |
| US-20120035115-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20110262366-A1 | COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THEIR USE | BRACCO INTERNATIONAL B.V. (NL) | 2011-10-27 | — | — | US | disclosed |
| US-7884183-B2 | also targeting tumor cells that express vascular endothelial growth factor neuropilin-1 receptor; radiotherapy; radiopharmaceuticals; treating angiogenesis | BRACCO SUISSE SA (CH) | 2011-02-08 | — | — | US | disclosed |
| US-20100311903-A1 | Photonic Shell-Core Cross Linked and Functionalized Nanostructures for Biological Applications | MALLINCKRODT LLC | 2010-12-09 | — | — | US | disclosed |
| US-7820621-B2 | Compounds for targeting endothelial cells, compositions containing the same and methods for their use | BRACCO INTERNATIONAL B.V. (NL) | 2010-10-26 | — | — | US | disclosed |
| WO-2006095234-A2 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO IMAGING S.P.A. (IT) | 2006-09-14 | — | — | WO | disclosed |
| US-5032498-A | Soluble stabilizers | CIBA-GEIGY CORPORATION (US) | 1991-07-16 | — | — | US | disclosed |
| US-4973702-A | AMIDES AND ESTERS, UV STABILIZERS FOR PLASTICS AND PHOTOGRAPHIC MATERIALS | CIBA-GEIGY CORPORATION (US) | 1990-11-27 | — | — | US | disclosed |
| US-4853471-A | 2-(2-Hydroxyphenyl)-benztriazoles, their use as UV-absorbers and their preparation | CIBA-GEIGY CORPORATION (US) | 1989-08-01 | — | — | US | disclosed |
| EP-0057160-B1 | 2-(2-HYDROXYPHENYL)-BENZOTRIAZOLES, THEIR USE AS ULTRAVIOLET STABILIZERS AND THEIR PREPARATION | CIBA-GEIGY AG (CH) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190275110-A1 | COMPOSITIONS IN THE FORM OF AN INJECTALE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID | GCG, GLP1R, IAPP | TSHR 287/4885CYP3A4 3539/4885DNM1 2667/4885 |
| US-20230381113-A1 | POLYMERS AND NANOPARTICLE FORMULATIONS FOR SYSTEMIC NUCLEIC ACID DELIVERY | SARNP, EEA1, PHAX | TSHR 3202/4885CYP3A4 4581/4885DNM1 1042/4885 |
| US-20230295105-A1 | PIPERIDINEDIONE DERIVATIVES | CRBN, CUL1, PSMB10 | TSHR 3860/4885CYP3A4 4750/4885DNM1 2444/4885 |
| US-11358988-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | TSHR 1977/4885CYP3A4 3990/4885DNM1 3369/4885 |
| US-20240067952-A1 | REPROGRAMMING UROKINASE INTO AN ANTIBODY-RECRUITING ANTICANCER AGENT | PLAUR, CD47, CD14 | TSHR 1054/4885CYP3A4 4736/4885DNM1 2864/4885 |
| US-20110262366-A1 | COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THEIR USE | VCAM1, FLT1, EDNRA | TSHR 1504/4885CYP3A4 4836/4885DNM1 640/4885 |
| US-20230250053-A1 | PROCESS FOR SYNTHESIZING TARGETING MOLECULES | RARG, RARA, RARB | TSHR 1440/4885CYP3A4 4109/4885DNM1 1743/4885 |
| US-20200216498-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | TSHR 1977/4885CYP3A4 3990/4885DNM1 3369/4885 |
| US-20120035115-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | DNMT1, LCK, MCTS1 | TSHR 3178/4885CYP3A4 2697/4885DNM1 1092/4885 |
| US-11083682-B2 | Composition and method for improving and protecting keratins | KRT18, CUTA, FASN | TSHR 2649/4885CYP3A4 2252/4885DNM1 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.